Other Income & Expense
Derivative Gain (Loss) Excluded from Effectiveness
Raytheon Technologies Derivative Gain (Loss) Excluded from Effectiveness increased by 2.5% to -$390.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.0%, from -$443.00M to -$390.00M. Over 2 years (FY 2023 to FY 2025), Derivative Gain (Loss) Excluded from Effectiveness shows a downward trend with a 7.8% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2023
Last reportedQ1 2026Apr 21, 2026
Metric ID:
abbv_derivative_gain_loss_excluded_from_effectivenessHistorical Data
13 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$376.25M | -$376.25M | -$376.25M | -$376.25M | -$405.00M | -$475.00M | -$496.00M | -$486.00M | -$443.00M | -$457.00M | -$449.00M | -$400.00M | -$390.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.6% | -17.3% | -4.4% | +2.0% | +8.8% | -3.2% | +1.8% | +10.9% | +2.5% |
| YoY Change | — | — | — | — | -7.6% | -26.2% | -31.8% | -29.2% | -9.4% | +3.8% | +9.5% | +17.7% | +12.0% |
Range-$496.00M – -$376.25M
CAGR+1.2%
Avg YoY Growth-6.8%
Median YoY Growth-7.6%
Current Streak3 quarters growth
Derivative Gain (Loss) Excluded from Effectiveness at Other Companies
Frequently Asked Questions
- What is Raytheon Technologies's derivative gain (loss) excluded from effectiveness?
- Raytheon Technologies (RTX) reported derivative gain (loss) excluded from effectiveness of -$390.00M in Q1 2026.
- How has Raytheon Technologies's derivative gain (loss) excluded from effectiveness changed year-over-year?
- Raytheon Technologies's derivative gain (loss) excluded from effectiveness increased by 12.0% year-over-year, from -$443.00M to -$390.00M.
- What is the long-term trend for Raytheon Technologies's derivative gain (loss) excluded from effectiveness?
- Over 2 years (2023 to 2025), Raytheon Technologies's derivative gain (loss) excluded from effectiveness has grown at a 7.8% compound annual growth rate (CAGR), from -$1.51B to -$1.75B.